Saturday 17 October 2026
Export CRBP’s income statement to Excel — free account
Corbus Pharmaceuticals Holdings, Inc.
CRBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.52
0.19
+4.39%
Follow CRBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(55.65%) | (54.18%) | (66.70%) | (95.58%) | |
| (49.34%) | (48.47%) | (59.44%) | (80.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(74.42%) | (53.64%) | (67.33%) | (100.55%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(4.84) | (4.84) | (3.94) | (4.47) | |
Free Cash Flow |
(59.51) | (64.49) | (73.65) | (86.69) | |
Capital Expenditures |
— | 0.00 | (0.01) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(30.30%) | (20.71%) | (27.80%) | (39.37%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.88 | 0.82 | 0.87 | 0.85 | |
Depreciation/Fixed assets |
(5.89) | (7.13) | (11.27) | (15.70) | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.84) | (4.84) | (3.94) | (4.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates